Dyne Therapeutics Announces Positive Initial Clinical Data f

- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown - - All Evaluable Patients in the 3.4 mg/kg Cohort Treated with DYNE-101...

Related Keywords

Milan , Lombardia , Italy , United States , Stacy Nartker , Wildon Farwell , Amy Reilly , Valeriaa Sansone , Joshua Brumm , Los Angeles , Perry Shieh , Exchange Commission , Gene Panel , Dyne Therapeutics Inc , Myotonic Dystrophy Health Index , Facebook , David Geffen School Of Medicine , European Medicines Agency , Nasdaq , University Of Milan , Clinical Center Ne , Drug Administration , Linkedin , Dose Dependent Splicing Correction , Muscle Delivery , Evaluable Patients , Cohort Treated , Demonstrated Consistent Splicing Correction , Mean Improvement Across , Lowest Dose , Mean Dystrophin Expression , Cohort Administered Monthly , Greater Than , Higher Dystrophin Than Reported , Weekly Administered Current Standard , Safety Profile , Supported Dose Escalation , Enrollment Complete , Webcast Event Today , Reported Outcome , Scientific Director , Clinical Center , David Geffen School , Ronald Reagan , Myotonic Dystrophy Type , Duchenne Muscular Dystrophy , Private Securities Litigation Reform Act , Markets ,